Potential of Moving Mirvetuximab to Earlier Lines in Ovarian Cancer Subtype

Video
Conference|ASCO Annual Meeting: Gynecologic Cancer

In addition to potentially moving mirvetuximab into earlier lines of treatment for those with platinum-sensitive ovarian cancer, Ritu Salani, MD, also discusses combining the agent with carboplatin to decrease toxicities and improve quality of life.

In an interview with CancerNetwork®, Ritu Salani, MD discusses moving mirvetuximab soravtansine-gynx (Elahere) to earlier lines of treatment to capitalize on improved outcomes with less adverse effects among patients with folate receptor–α platinum-resistant ovarian cancer based on findings from the phase 3 MIRASOL trial (NCT04209855).

Investigators presented data from the MIRASOL trial at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

According to Salani, the Gynecologic Oncology Fellowship Director at University of California Los Angeles Health and the Gynecologic Oncology editorial board member for the journal ONCOLOGY®, ongoing trials combining mirvetuximab with agents such as carboplatin may help elucidate the feasibility of treating platinum-sensitive disease in earlier settings while minimizing toxicity among patients.

In the MIRASOL trial, patients treated with mirvetuximab experienced an overall response rate of 42% compared with 16% among those treated with investigator’s choice chemotherapy. Moreover, Salani emphasized that patients who previously received bevacizumab (Avastin) did not respond as well as the overall population, but still showed favorable outcomes.

Transcript:

The one thing we always see is that when we have an active agent, we want to use it as early as possible. One of the things that came out with this trial is that the patients who received bevacizumab before proceeding with mirvetuximab had a little bit of a lower response rate, although it was still a favorable response rate than those who are bevacizumab naïve. One of the concepts of this is maybe we should move mirvetuximab sooner; that is where the trials are headed.

There are currently studies of moving mirvetuximab in combination with carboplatin earlier to the platinum-sensitive [population] and exploring [the question of] if we use a drug sooner, can we even capitalize on these better outcomes, especially for minimizing toxicities? One of the really great things about the ovarian cancer landscape is that patients are living a lot longer. If we can reduce toxicities in these patients and allow them to live better, not just longer, we're really making the impact in this disease.

Reference

Moore KN, Angelergues A, Konecny GE, et al. Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: mirvetuximab soravtansine vs. investigator’s choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression. J Clin Oncol. 2023;41(suppl 17):LBA5507. doi:10.1200/JCO.2023.41.17_suppl.LBA5507

Recent Videos
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
According to John Henson, MD, “What we need are better treatments to control the [brain] tumor once it’s detected.”
First-degree relatives of patients who passed away from pancreatic cancer should be genetically tested to identify their risk for the disease.
Surgery and radiation chemotherapy can affect immunotherapy’s ability to target tumor cells in the nervous system, according to John Henson, MD.
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Related Content
Investigators noted 1 instance of rectovaginal fistula in the PEG gel arm, although rapid postoperative recovery occurred.

PEG Hydrogel Reduces Rectal Radiation During Cervical Cancer Therapy

Russ Conroy
November 27th 2025
Article

Investigators noted 1 instance of rectovaginal fistula in the PEG gel arm, although rapid postoperative recovery occurred.

Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.

What Were The Most Impactful GU Oncology Data From ESMO 2025?

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
November 6th 2025
Podcast

Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.

Deeper short-term declines in quality of life occurred when combining cisplatin with radiation for those with intermediate-risk cervical cancer.

Radiation ± Chemotherapy Shows Worse Short-Term QOL in Cervical Cancer

Russ Conroy
November 22nd 2025
Article

Deeper short-term declines in quality of life occurred when combining cisplatin with radiation for those with intermediate-risk cervical cancer.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

The median PFS for patients with ovarian cancer who received niraparib maintenance in the real-world setting was 25.7 months.

Real-World Niraparib Efficacy Similar to Phase 3 Data in Ovarian Cancer

Tim Cortese
November 18th 2025
Article

The median PFS for patients with ovarian cancer who received niraparib maintenance in the real-world setting was 25.7 months.

The 3-year DFS rate was 96.9% in patients who received sentinel-lymph node biopsy alone vs 94.6% in those who received lymphadenectomy.

Omitting Lymphadenectomy Reduces AEs, Does Not Lower DFS in Cervical Cancer

Tim Cortese
November 18th 2025
Article

The 3-year DFS rate was 96.9% in patients who received sentinel-lymph node biopsy alone vs 94.6% in those who received lymphadenectomy.